RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Multiple Myeloma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma.
Garikipati Naga Alekhya et al., Annals of African medicine (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42893828/
- 2.
Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos Meletios Athanasios et al., Blood cancer journal (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42892628/
- 3.
Clinicopathological Characteristics of IgD Lambda Multiple Myeloma: Experience from A Tertiary Care Centre
Nithye Parvathy et al., Indian Journal of Hematology and Blood Transfusion (16 October 2026)
https://doi.org/10.1007/s12288-026-02608-z
- 4.
Association between blood urea nitrogen and prognosis in critical patients with multiple myeloma: a retrospective cohort study
Haiyan Ding et al., BMC Cancer (16 October 2026)
https://doi.org/10.1186/s12885-026-17200-x
- 5.
An omics-guided cytokine platform for sustained ex vivo culture and functional modeling of primary multiple myeloma patient cells
Ariene Dol Cabantog, Open Collections (16 October 2026)
https://doi.org/10.14288/1.0456596
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
NCT07681596 · Recruiting · Phase 1 / Phase 2 · AstraZeneca
Ages 18 and over
https://clinicaltrials.gov/study/NCT07681596
- 2.
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634 · Recruiting · Phase 2 · Janssen Research & Development, LLC
Ages 18 and over
https://clinicaltrials.gov/study/NCT07589634
- 3.
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978 · Recruiting · Phase 3 · AstraZeneca
Ages 18 and over
https://clinicaltrials.gov/study/NCT07764978
- 4.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938 · Recruiting · Phase 3 · Hoffmann-La Roche
Ages 18 and over
https://clinicaltrials.gov/study/NCT07555938
- 5.
A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07558915 · Recruiting · Phase 1 · Genentech, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT07558915
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Multiple Myeloma
Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow. The abnormal cells crowd the marrow and produce a faulty antibody, which can lead to bone pain and fractures, anaemia, infections, and kidney problems. Treatment usually combines medicines that target myeloma cells with supportive care for the bones, and sometimes a stem cell transplant.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite many advances in immunotherapies. Outcomes are particularly dismal in patients who are refractory to these three major classes of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies (mAbs), and chimeric antigen receptor (CAR) T-cell therapies. Novel bispecific antibodies (BsAbs) have shown some promising efficacy in heavily pretreated patients, even those with triple- and penta-refractory disease. Talquetamab is a BsAb recently approved for the treatment of relapsed and refractory multiple myeloma. Talquetamab demonstrated a high overall response rate of approximately 70%, including in patients that are previously treated with T-cell therapies. The safety profile of talquetamab is consistent with other BsAbs, with similar adverse events. The efficacy of talquetamab and other therapies, including CAR-T cell treatments, remains an area of active research, as resistance to anti-B-cell maturation antigen therapies poses a clinical challenge. Current trials are exploring the use of talquetamab in combination therapies. There is now adequate data to further support talquetamab's efficacy, making it a very important addition to the RRMM treatment domain.
Common Questions
What is Multiple Myeloma?
Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow. The abnormal cells crowd the marrow and produce a faulty antibody, which can lead to bone pain and fractures, anaemia, infections, and kidney problems. Treatment usually combines medicines that target myeloma cells with supportive care for the bones, and sometimes a stem cell transplant.
How many clinical trials are available for Multiple Myeloma?
RareWays currently indexes 3161 clinical trials for Multiple Myeloma, of which 414 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Multiple Myeloma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Multiple Myeloma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.